Tizon, Candido T.
HRN: 14-84-09 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/12/2024
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
03/12/2024
03/18/2024
IV
4.5g LD, Then 2.25g
Q8h
CAP MR, Covid 19 Infection, T/C UTI, (Ceftriaxone Given Last Admission Feb 2024)
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes